Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.
Saved in:
| Title: | Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial. |
|---|---|
| Authors: | Yen CJ; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. yencj@mail.ncku.edu.tw.; National Cheng Kung University Hospital Cancer Center, Tainan, Taiwan. yencj@mail.ncku.edu.tw., Chen MH; Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan., Chen YY; Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan., Bai LY; Division of Hematology and Oncology, China Medical University Hospital, China Medical University, Taichung, Taiwan., Chen JS; Hematology-Oncology, Linkou Chang Gung Memorial Hospital & Chang Gung University, Taoyuan, Taiwan., Hsieh JC; Division of Hematology-Oncology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.; School of Medicine, National Tsing Hua University, Hsinchu, Taiwan., Shih YH; Hematology and Medical Oncology, Taichung Veterans General Hospital, Taichung, Taiwan., Wu IC; Gastroenterology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan., Chen YL; TaiRx, Inc., Nankang Business Park, Taipei, Taiwan., Chen CM; TaiRx, Inc., Nankang Business Park, Taipei, Taiwan., Chao TY; TaiRx, Inc., Nankang Business Park, Taipei, Taiwan., Chu YW; TaiRx, Inc., Nankang Business Park, Taipei, Taiwan., Chien DS; TaiRx, Inc., Nankang Business Park, Taipei, Taiwan. |
| Source: | British journal of cancer [Br J Cancer] 2026 Jul 02. Date of Electronic Publication: 2026 Jul 02. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
